Licence Agreement Sample Contracts

Denali Therapeutics Inc. – AMENDED AND RESTATED GAMMA IP LICENCE AGREEMENT Among F-Star BIOTECHNOLOGY LIMITED, and F-Star GAMMA LIMITED, Dated as of 24 August 2016 (August 9th, 2018)

THIS AMENDED AND RESTATED LICENSE AGREEMENT is made and entered into effective as of 24 August 2016 (the "Effective Date") by and between

Eurosport Active World Corp – Addendum to Technology Transfer and Licence Agreement (August 1st, 2018)

This Addendum to the Technology Transfer and License Agreement (the "Agreement") is made and effective on January 29th, 2016; and supersede the previous addendum dated on June 29th, 2015.

Eurosport Active World Corp – Addendum to Technology Transfer and Licence Agreement (August 1st, 2018)

This Addendum to the Technology Transfer and License Agreement (the "Agreement") is made and effective on June 29th, 2015; and supersede the previous addendum dated on December 12th 2014.

MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and MeiraGTx UK II Limited and MeiraGTx Limited Dated: 15 March 2018 Ref: (May 29th, 2018)

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and Athena Vision Ltd Dated 4 February 2015 (May 29th, 2018)

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and MeiraGTx UK II Limited Dated: 28th July 2017 Ref: (May 29th, 2018)
MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and MeiraGTx UK II Limited Dated: 28th July 2017 Ref: (April 13th, 2018)
MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and MeiraGTx UK II Limited and MeiraGTx Limited Dated: 15 March 2018 Ref: (April 13th, 2018)

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENCE AGREEMENT Between UCL Business Plc and Athena Vision Ltd Dated 4 February 2015 (April 13th, 2018)

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

NuCana BioMed Ltd – Research, Collaboration and Licence Agreement (March 22nd, 2018)
NuCana BioMed Ltd – Research, Collaboration and Licence Agreement THIS AGREEMENT Is Made This 21st Day of August 2009 BETWEEN: (September 18th, 2017)
NuCana BioMed Ltd – Research, Collaboration and Licence Agreement THIS AGREEMENT Is Made This 21st Day of August 2009 BETWEEN: (September 1st, 2017)
NuCana BioMed Ltd – Research, Collaboration and Licence Agreement THIS AGREEMENT Is Made This 21st Day of August 2009 BETWEEN: (August 4th, 2017)
Calyxt, Inc. – Confidential Treatment Requested Under Rule 406 Under the Securities Act of 1933, as Amended. [*****] Indicates Omitted Material That Is the Subject of a Confidential Treatment Request Filed Separately With the Commission. The Omitted Material Has Been Filed Separately With the Commission. Exclusive Licence Agreement (July 3rd, 2017)

PLANT BIOSCIENCE LIMITED, a company registered in England with number 2896390 and whose registered office is at John Innes Centre, Norwich Research Park, Colney Land, Norwich NR4 7UH, UK (hereinafter PBL) and

Calyxt, Inc. – Confidential Treatment Requested Under Rule 406 Under the Securities Act of 1933, as Amended. [*****] Indicates Omitted Material That Is the Subject of a Confidential Treatment Request Filed Separately With the Commission. The Omitted Material Has Been Filed Separately With the Commission. Exclusive Licence Agreement (June 23rd, 2017)

CALYXT, INC. (formerly named CELLECTIS PLANT SCIENCES), a company existing and registered under the laws of Delaware, located at [*****], under the [*****] (hereinafter CALYXT).

Calyxt, Inc. – Confidential Treatment Requested Under Rule 406 Under the Securities Act of 1933, as Amended. [*****] Indicates Omitted Material That Is the Subject of a Confidential Treatment Request Filed Separately With the Commission. The Omitted Material Has Been Filed Separately With the Commission. Exclusive Licence Agreement (June 16th, 2017)

CALYXT, INC. (formerly named CELLECTIS PLANT SCIENCES), a company existing and registered under the laws of Delaware, located at [*****], under the [*****] (hereinafter CALYXT).

Lion Consulting Group – Licence Agreement (May 5th, 2017)
Biohaven Pharmaceutical Holding Co Ltd. – Licence Agreement (April 7th, 2017)

This License Agreement (the Agreement) is made and entered into effective as of 5 October 2016 (the Effective Date) by and between AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden and with offices at SE-431 83 Molndal, Sweden (AstraZeneca) and BioHaven Pharmaceutical Holding Company Ltd. a British Virgin Islands business corporation with a registered office address of P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands (Licensee). AstraZeneca and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

Biohaven Pharmaceutical Holding Co Ltd. – Licence Agreement (April 3rd, 2017)

This License Agreement (the Agreement) is made and entered into effective as of 5 October 2016 (the Effective Date) by and between AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden and with offices at SE-431 83 Molndal, Sweden (AstraZeneca) and BioHaven Pharmaceutical Holding Company Ltd. a British Virgin Islands business corporation with a registered office address of P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands (Licensee). AstraZeneca and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

Verona Pharma plc – INTELLECTUAL PROPERTY ASSIGNMENT AND LICENCE AGREEMENT DATED 7TH FEBRUARY, 2005 VERNALIS DEVELOPMENT LIMITED and RHINOPHARMA LTD. (April 3rd, 2017)
Verona Pharma plc – INTELLECTUAL PROPERTY ASSIGNMENT AND LICENCE AGREEMENT DATED 7TH FEBRUARY, 2005 VERNALIS DEVELOPMENT LIMITED and RHINOPHARMA LTD. (November 23rd, 2016)
First Amendment to the Licence Agreement (November 10th, 2016)

THIS FIRST AMENDMENT to the LICENSE AGREEMENT with an Effective Date of October 15, 2014 is made as of this July 6, 2015 ("Effective Date of the Amendment"), by and between the UNIVERSITY OF MISSISSIPPI, and CHROMADEX, INC. concerning a blue green algae technology.

Leap Therapeutics, Inc. – LICENCE AGREEMENT Between LONZA SALES AG and HEALTHCARE PHARMACEUTICALS, INC. (November 2nd, 2016)

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as Lonza), and

Licence Agreement (October 6th, 2016)

Clause 1. Interpretation 3 2. Licence and Licence Restrictions 5 3. Products & Services 7 4. ET Data, Data Protection & Privacy 7 5. Third party providers 9 6. ValidSoft's obligations 9 7. ET's obligations 10 8. Charges and payment 11 9. ValidSoft Proprietary rights 11 10. Confidentiality 12 11. Indemnity 13 12. Limitation of liability 14 13. termination 15 14. Force majeure 17 15. Conflict 17 16. Variation or Amendment 17 17. Waiver 17 18. Rights and remedies 18 19. Severance 18 20. Entire agreement 18 21. Assignment 18 22. No partnership or agency 18 23. Third party rights 19 24. Notices 19 25. Governing law 19 26. Jurisdiction; Waiver of Jury Trial

Leap Therapeutics, Inc. – LICENCE AGREEMENT Between LONZA SALES AG and HEALTHCARE PHARMACEUTICALS, INC. (September 26th, 2016)

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as Lonza), and

Hemispherx BioPharma, Inc. – LICENCE AGREEMENT Between LONZA SALES AG and Hemispherx Biopharma, Inc (August 29th, 2016)

{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Hemispherx BioPharma, Inc. – LICENCE AGREEMENT {***} Between and Hemispherx Biopharma, Inc (May 16th, 2016)

{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Leave and Licence Agreement (May 12th, 2016)

THIS AGREEMENT made on this 5th day of March, 2016 BETWEEN GODREJ & BOYCE MANUFACTURING COMPANY LTD. (PAN Number - AAACG1395D), a Company incorporated under the provisions of the Indian Companies Act, 1913, and having its Registered Office at Pirojshanagar, Vikhroli, Mumbai 400079 hereinafter referred to as the Licensor (which expression shall unless it be repugnant to the context or meaning thereof, be deemed to include their successors and permitted assigns) of the ONE PART;

Leave and Licence Agreement (May 12th, 2016)

THIS AGREEMENT made on this 8th day of March, 2016 BETWEEN GODREJ & BOYCE MANUFACTURING COMPANY LTD. (PAN Number - AAACG1395D), a Company incorporated under the provisions of the Indian Companies Act, 1913, and having its Registered Office at Pirojshanagar, Vikhroli, Mumbai 400079 hereinafter referred to as the Licensor (which expression shall unless it be repugnant to the context or meaning thereof, be deemed to include their successors and permitted assigns) of the ONE PART;

Leave and Licence Agreement (May 12th, 2016)

THIS AGREEMENT made on this 8th day of March, 2016 BETWEEN GODREJ & BOYCE MANUFACTURING COMPANY LTD. (PAN Number - AAACG1395D), a Company incorporated under the provisions of the Indian Companies Act, 1913, and having its Registered Office at Pirojshanagar, Vikhroli, Mumbai 400079 hereinafter referred to as the Licensor (which expression shall unless it be repugnant to the context or meaning thereof, be deemed to include their successors and permitted assigns) of the ONE PART;

Phaserx, Inc. – Amended and Restated RAFT Non-Exclusive Licence Agreement (April 18th, 2016)

1 Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 5 2 Term 6 2.1 Term of Agreement 6 2.2 Patents and patent applications separately licensed 6 3 Licence grant 6 3.1 Grant of licence 6 3.2 Sublicensing rights to manufacture 6 3.3 Sublicensing rights to make and sell Licensed Products 7 3.4 Sale of Licensed Products 8 4 PhaseRx obligations 8 4.1 Responsibilities and acknowledgements 8 4.2 Performance 9 4.3 RAFT Improvements 9 4.4 Annual progress reporting 9 5 Royalties and payments 9 5.1 Royalties and payments 9 5.2 Royalty offset 10 5.3

Adaptimmune Therapeutics PLC – AGREEMENT BETWEEN: ADAPTIMMUNE LIMITED (1) and UNIVERSAL CELLS, INC. (2) RESEARCH COLLABORATION AND LICENCE AGREEMENT RELATING TO GENE EDITING AND HLA- ENGINEERING TECHNOLOGY (March 17th, 2016)

This RESEARCH COLLABORATION AND LICENCE AGREEMENT (the Agreement) is made as of the 25th day of November 2015 (the Effective Date) by and between:

Phaserx, Inc. – Amended and Restated RAFT Non-Exclusive Licence Agreement (February 12th, 2016)

1 Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 5 2 Term 6 2.1 Term of Agreement 6 2.2 Patents and patent applications separately licensed 6 3 Licence grant 6 3.1 Grant of licence 6 3.2 Sublicensing rights to manufacture 6 3.3 Sublicensing rights to make and sell Licensed Products 7 3.4 Sale of Licensed Products 8 4 PhaseRx obligations 8 4.1 Responsibilities and acknowledgements 8 4.2 Performance 9 4.3 RAFT Improvements 9 4.4 Annual progress reporting 9 5 Royalties and payments 9 5.1 Royalties and payments 9 5.2 Royalty offset 10 5.3

2304101 Ontario Inc. – LICENCE AGREEMENT Made This 24st Day of April, 2015 (November 16th, 2015)

AND WHEREAS the University is willing to provide the use of 21.28 square metres /229.06 square feet assignable floor area comprising Room 302 covering the period May 1, 2015 to April30, 2016 to be used as office space, including all existing furnishings and equipment (if any), and being located on the second (2nd) level of the Banting Institute at 100 College Street, as shown cross-hatched on Schedule "A" attached hereto (the "Licenced Premises") to the Corporation under licence from the University and upon the terms and conditions hereinafter set forth;

Cytodyn Inc – LICENCE AGREEMENT Between LONZA SALES AG and CYTODYN INC. (August 19th, 2015)

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as Lonza), and